11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

      Nature reviews. Cancer

      Antibodies, Monoclonal, therapeutic use, Antibodies, Monoclonal, Humanized, Dimerization, Female, HSP90 Heat-Shock Proteins, antagonists & inhibitors, Humans, Male, Neoplasms, drug therapy, etiology, Phosphatidylinositol 3-Kinases, physiology, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Receptor, ErbB-2, chemistry, Receptor, ErbB-3, Signal Transduction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody-chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2-ERBB3 dimers.

          Related collections

          Author and article information

          Journal
          19536107
          10.1038/nrc2656

          Comments

          Comment on this article